Auris Medical Holding to Present at LD Micro Invitational XI Conference
Auris Medical Holding Ltd. (NASDAQ: EARS) announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on June 9, 2021, at 11:00 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Auris Medical Holding Ltd. (NASDAQ: EARS) announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on June 9, 2021, at 11:00 a.m. EST. This presentation will be webcast live, accessible through the event homepage. Auris Medical, focused on therapeutics for neurotology, rhinology, allergy, and CNS disorders, is developing intranasal betahistine for vertigo treatment and protecting against airborne viruses with its nasal spray Bentrio. The company also has two Phase 3 programs for hearing loss and tinnitus.
Details
News Market Reaction – EARS
The recorded move for EARS in the trading session of this news was +2.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.
About Auris Medical
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens BentrioTM (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.